Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL36A-HNRNPH2 readthrough is a locus on chromosome X formed by natural read-through transcription between the adjacent genes encoding ribosomal protein L36a and heterogeneous nuclear ribonucleoprotein H2[4][5]. The resulting transcript produces a protein similar to RPL36A, a ribosomal structural protein involved in protein synthesis[2][4][5]. Alternatively spliced transcript variants exist. The locus is implicated as a genomic region associated with Fabry disease and intellectual developmental disorder, though no evidence exists for direct drug targeting or receptor activity[1][5]. Regulatory elements in this region may affect the expression of disease-relevant neighboring genes such as *GLA* (alpha-galactosidase A)[1]. In summary, **RPL36A-HNRNPH2 readthrough** is best classified as a structural ribosomal protein from a readthrough locus with disease associations, but it does not conform to the usual categories of therapeutic drug targets, such as receptor, enzyme, or ion channel[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RPL36A-HNRNPH2 readthrough (RPL36A-HNRNPH2).